Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Fazio

Showing results (81-90 of 284) with videos related to

Pageof 29
Sort By:
American Journal of Preventive Cardiology|April 4, 2022
Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 updateJing Gu, Robert Sanchez, Ankita Chauhan, et al.
Journal of the American College of Cardiology|July 18, 2018
The Evolving Future of PCSK9 InhibitorsRobert S Rosenson, Robert A Hegele, Sergio Fazio, et al.
Endocrine Reviews|October 13, 2018
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease RiskPratik B Sandesara, Salim S Virani, Sergio Fazio, et al.
Metabolism: Clinical and Experimental|February 1, 2018
Balanced high fat diet reduces cardiovascular risk in obese women although changes in adipose tissue, lipoproteins, and insulin resistance differ by raceKevin D Niswender, Sergio Fazio, Barbara A Gower, et al.
Diabetes, Obesity & Metabolism|September 19, 2018
Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterolGregory A Nichols, Sephy Philip, Kristi Reynolds, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 2018
Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL CholesterolGregory A Nichols, Sephy Philip, Kristi Reynolds, et al.
Journal of the American College of Cardiology|January 29, 2025
Reply: Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With CautionDoron Zahger, Gregory G Schwartz, Michael Szarek, et al.
Cardiovascular Research|August 7, 2016
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol loweringGiuseppe Danilo Norata, Hagai Tavori, Angela Pirillo, et al.
Journal of Clinical Lipidology|November 1, 2022
Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular diseaseJing Gu, Robert J Sanchez, Ankita Chauhan, et al.
The Journal of Biological Chemistry|October 27, 2011
Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) proteinFen Du, Yvonne Hui, Michelle Zhang, et al.
Pageof 29

Showing results (81-90 of 284) with videos related to

Sort By:
Pageof 29
American Journal of Preventive Cardiology|April 4, 2022
Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 updateJing Gu, Robert Sanchez, Ankita Chauhan, et al.
Journal of the American College of Cardiology|July 18, 2018
The Evolving Future of PCSK9 InhibitorsRobert S Rosenson, Robert A Hegele, Sergio Fazio, et al.
Endocrine Reviews|October 13, 2018
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease RiskPratik B Sandesara, Salim S Virani, Sergio Fazio, et al.
Metabolism: Clinical and Experimental|February 1, 2018
Balanced high fat diet reduces cardiovascular risk in obese women although changes in adipose tissue, lipoproteins, and insulin resistance differ by raceKevin D Niswender, Sergio Fazio, Barbara A Gower, et al.
Diabetes, Obesity & Metabolism|September 19, 2018
Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterolGregory A Nichols, Sephy Philip, Kristi Reynolds, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 2018
Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL CholesterolGregory A Nichols, Sephy Philip, Kristi Reynolds, et al.
Journal of the American College of Cardiology|January 29, 2025
Reply: Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With CautionDoron Zahger, Gregory G Schwartz, Michael Szarek, et al.
Cardiovascular Research|August 7, 2016
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol loweringGiuseppe Danilo Norata, Hagai Tavori, Angela Pirillo, et al.
Journal of Clinical Lipidology|November 1, 2022
Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular diseaseJing Gu, Robert J Sanchez, Ankita Chauhan, et al.
The Journal of Biological Chemistry|October 27, 2011
Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) proteinFen Du, Yvonne Hui, Michelle Zhang, et al.
Pageof 29